Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)
Status:
Completed
Trial end date:
2016-12-21
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to find out the effects of a drug called
panobinostat (LBH589) when given to people like you with multiple myeloma in combination with
the drugs lenalidomide and dexamethasone. The safety of this combination of drugs will also
be studied. Your physical state, changes in the state of your multiple myeloma, and
laboratory findings taken while on-study will help us decide if panobinostat combined with
dexamethasone and lenalidomide is safe and effective.
This goal of this study therefore is to determine the activity of the combination of
panobinostat thrice weekly every other week, lenalidomide, and weekly dexamethasone in a
similar group of subjects. The doses of lenalidomide and dexamethasone will be that which is
approved by the FDA for multiple myeloma and you will take each drug at a specific frequency
over a 4 week (28 day) period. This period is called a "study cycle".